[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650956":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":11,"centralContacts":34,"locations":11,"responsibleParty":40,"collaborators":11,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":11,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":11,"overallStatus":62,"whyStopped":11,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":11},{"fullName":5,"class":6},"Shattuck Labs, Inc.","INDUSTRY",[8,14,17,20],{"label":9,"type":10,"description":11,"interventionNames":12},"SL-325 high dose","EXPERIMENTAL",null,[13],"Drug: SL-325",{"label":15,"type":10,"description":11,"interventionNames":16},"SL-325 mid dose",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"SL-325 low dose",[13],{"label":21,"type":22,"description":11,"interventionNames":23},"Placebo","PLACEBO_COMPARATOR",[24],"Drug: Placebo",[26,31],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":11},"DRUG","SL-325","SL-325 administered intravenously",[9,18,15],{"type":27,"name":21,"description":32,"armGroupLabels":33,"otherNames":11},"Placebo administered intravenously",[21],[35],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"Shattuck Medical Director","CONTACT","919-864-2700","clinicaltrials@shattucklabs.com",{"type":41,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100650956","a-phase-2-study-of-sl-325-in-crohns-disease-patients-100650956",false,"NCT07753850","A Study of SL-325 in Crohn's Disease Patients","A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderately to Severely Active Crohn's Disease","RECEPTIVE-CD1","Key Inclusion Criteria:\n\n* A diagnosis of Crohn's disease confirmed by endoscopy and histopathology ≥ 3 months prior to Screening\n* Moderately to severely active CD as defined by CDAI of ≥ 220 and ≤ 450\n* SES-CD score ≥ 6 if ileocolonic or colonic disease, or ≥ 4 if isolated ileal disease, as assessed by central review\n* Demonstrated inadequate response, loss of response, or intolerance to one or more of the following Crohn's disease treatments: corticosteroids, immunomodulators, or an approved anti-tumor necrosis factor (TNF), anti-integrin, anti-interleukin (IL)-12\u002F23, anti-interleukin (IL)-23p19, or Janus kinase inhibitor (JAK)\n\nKey Exclusion Criteria:\n\n* Diagnosis of UC, indeterminate colitis, or any other gastrointestinal condition that could undermine the diagnosis of CD\n* CD isolated to the stomach, duodenum, jejunum, or perianal region, without colonic and\u002For ileal involvement\n* Presence or suspicion of any of the following CD complications: intra-abdominal or perianal abscess; symptomatic stricture or colonic stenosis not passable in ileocolonoscopy, fistula, except for perianal fistula; active toxic megacolon or fulminant colitis; short bowel syndrome\n* Surgical bowel resection within 3 months before Screening, ≥ 3 bowel resections, or previous ileo-colonic resection of \\> 2 segments\n* Diagnosis of primary sclerosing cholangitis\n* Has a stoma, ileostomy, or colostomy.\n* Has prior or current gastrointestinal dysplasia, other than a completely removed low-grade dysplastic lesion.\n* Has active tuberculosis (TB) or inadequately treated latent tuberculosis (LTBI)\n* Prior exposure to any anti-DR3 or anti-TL1A agent or agent with an anti-DR3 or anti-TL1A component","ALL","18 Years","80 Years",{"count":54,"type":55},232,"ESTIMATED","INTERVENTIONAL",[58],"PHASE2","The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease.\n\nThe study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.",[61],"Crohn's Disease","NOT_YET_RECRUITING","2026-08-10",{"date":65,"type":66},"2026-08-12","ACTUAL",{"date":68,"type":55},"2026-10",{"date":70,"type":55},"2030-06",{"name":5,"class":6}]